Immune‐related toxicity profile after haematopoietic stem cell transplantation in patients with B‐ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab
Olayinka Okeleji(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Jeremy Connors(The University of Texas MD Anderson Cancer Center), David McCall(The University of Texas MD Anderson Cancer Center), Amber Gibson(The University of Texas MD Anderson Cancer Center), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
|The Lancet Haematology|2019|83
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|Cancers|2021|66
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
|Nature Reviews Clinical Oncology|2021|59
Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances
|International Journal of Molecular Sciences|2023|54